Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise

MT Newswires Live

08/29

Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.

Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.

Analysts at Visible Alpha forecasted a loss of 1.01 yuan.

Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.

Analysts at Visible Alpha estimated 545.9 million yuan in revenue.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2563962970"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563962970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563962970?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563962970","market":"nz","top_or_hot":-1,"title":"Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise","media":"MT Newswires Live","content":"<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-29 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2563962970","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563962970","pubTimestamp":1756431367,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Everest Medicines  reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀","MDCO":"麦迪逊医药"},"translate_title":"Everest Medicines上半年亏损收窄，收入大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9,"MDCO":1},"content_text":"Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}